Product
Atrasentan
Aliases
ABT-627, Atrasentan Hydrochloride, CHK-01
4 clinical trials
6 indications
Indication
IgA NephropathyIndication
focal segmental glomerulosclerosisIndication
Alport SyndromeIndication
Diabetic NephropathyIndication
Diabetic Nephropathy Type 2Indication
Renal Cell CarcinomaClinical trial
A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular DiseasesStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Phase II Trial Evaluating Atrasentan In Patients With Advanced Renal Cell CarcinomaStatus: , Estimated PCD: 2006-04-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal FunctionStatus: Active (not recruiting), Estimated PCD: 2023-09-07